Clinical Trials · NCT02597803
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- ReGenTree, LLC
- Enrollment
- 317
- Start date
- Sep 2015
- Locations
- 1 site, United States
- Primary endpoint
- Total corneal fluorescein staining score at day29